Ref | Author year | How were IPD participants selected? | Percentage of male | Age median (years) | Age mean (years) | Age range (years) | Sample site | PCR test type; name of equipment if reported | Genomic targets; primers reported/referenced/ included |
---|---|---|---|---|---|---|---|---|---|
[9] | Cai 2020 | IPD of almost all patients in study | NR | NR | NR | NR | Not reported | qRT-PCR; not reported | ORF1ab, N-gene; not reported |
[16] | Chang 2020 | IPD of all patients in study | 69 | 36 | Not reported | IQR 24–43 | Throat | qRT-PCR; not reported | Not reported; not reported |
[10] | Chen 2020a | Initial or follow-up positive sputum or faecal samples paired with a follow-up negative pharyngeal sample | 64 | 37 | 37 | IQR 30–49 | Faeces, sputum, URT (pharyngeal) | qRT-PCR; not reported | ORF1ab, N-gene; not reported |
[12] | Chen 2020b | IPD of all patients in study | 51 | 51 |  | IQR 36–64 | URT | qRT-PCR; not reported | ORF1ab, N-gene; not reported |
[29] | He 2020 | IPD for all 94 patients presented, but could only extract 19 IPD from overlapping graphs | 50 | 47 | Â | Â | Throat | qRT-PCR; not reported | N-gene; not reported |
[24] | Hu 2020a | IPD of all patients in study | 48 | 46 | NR | NR | Nasopharyngeal | qRT-PCR; not reported | ORF1ab, N-gene; not reported |
[30] | Hu 2020b | IPD of almost all patients in study | 33 | 33 | 38 | 5–95 | Throat | qRT-PCR; BGI Genomics | ORF1ab; primers included |
[28] | Jiehao 2020 | IPD of all patients in study | 40 | 7 | 6 | 3 months–11 years | URT | qRT-PCR; not reported | ORF1ab, N-gene; not reported |
[31] | Kujawski 2020 | IPD of all patients in study | 67 | 53 |  | 21–68 | Throat, nasopharyngeal, sputum, urine, faeces | qRT-PCR; not reported | N-gene; not reported |
[39] | Lavezzo 2020 | All residents identified with infection | 50 | NR | NR | NR | Nasopharyngeal | qRT-PCR; One Step Real Time kit (Thermo Fisher Scientific, USA) | E-gene, RdRp; primers referenced |
[27] | Lescure 2020 | IPD of all patients in study | 60 | 46 | 47 | 30–80 | Nasopharyngeal, faeces, conjunctiva, urine, blood, LRT (pleural) | qRT-PCR; not reported | E-gene, RdRp; primers included |
[34] | Li 2020 | IPD of all patients in study | 57 | 42 | 43 | 21–62 | Throat | qRT-PCR; not reported | Not reported; not reported |
[14] | Liu 2020a | 25 participants with serial samples tested for PCR | NR | NA | NA | NA | Nasopharyngeal | qRT-PCR; not reported | Not reported; not reported |
[32] | Liu 2020b | IPD of all patients in study | 40 | 42 |  | 34–50 | Mixed URT (nasal, throat) | qRT-PCR; not reported | E-gene, RdRp, N-gene; not reported |
[18] | Lo 2020 | IPD of all patients in study | 30 | 54 | NR | NR | Faeces, nasopharyngeal, urine | qRT-PCR; BioGerm | ORF1ab, N-gene; not reported |
[20] | Lu 2020 | IPD of all patients in study | NR | NR | NR | NR | Sputum, URT (pharyngeal), faeces, blood | qRT-PCR; not reported | ORF1ab, N-gene; primers included |
[19] | Song 2020 | IPD of all patients in study | 100 | NR | NR | 22–67 | URT (pharyngeal) | qRT-PCR; Huirui biotechnology | Not reported; not reported |
[13] | To 2020 | IPD of all patients in study | 58 | 63 | Â | 37 to 75 | Saliva | qRT-PCR; QuantiNova SYBR Green RT-PCR kit (Qiagen) | S-gene; not reported |
[17] | Wolfel 2020 | IPD of all patients in study | NR | Not reported | Not reported | Not reported | Sputum, faeces, URT (pharyngeal) | qRT-PCR; Tib-Molbiol, Germany | E-gene, RdRp; not reported |
[37] | Wu 2020 | Retrospective 41 patients with positive faecal samples only | 53 | NR | NR | NR | Throat, faeces | qRT-PCR; 2019-nCOV Real Time RT-PCR kit (LifeRiver Ltd) | E-gene, RdRp, N-gene |
[40] | Wyllie 2020 | Patients with multiple nasopharyngeal swabs or multiple saliva swabs | Inpatients (52), healthcare workers (16) | NR | 61 | 23–92 | Nasopharyngeal, saliva | qRT-PCR; US CDC RT-PCR primer/probe sets | N-gene; primers referenced |
[21] | Xia 2020 | IPD of all patients in study | 70 | 51 | 55 | 13–83 | Sputum, conjunctiva | qRT-PCR; BioGerm | Not reported; not reported |
[23] | Xiao 2020 | IPD of all patients in study | 61 | 55 | 55 | 25–83 | URT (pharyngeal) | qRT-PCR; Shanghai Huirui Biotechnology Co. | ORF1ab, N-gene; not reported |
[33] | Xu 2020a | IPD of almost all patients in study | 49 | 3 groups: imported 35 [29–51], secondary 37 [24–47.5], tertiary 53 [35–65] |  | 24–65 | Throat | qRT-PCR; BioGerm | ORF1ab, N-gene; not reported |
[36] | Xu 2020b | IPD of all patients in study | 60 | 7 | 8 | 2 months–16 years | Nasopharyngeal, faeces | qRT-PCR; BioGerm | ORF1ab, N-gene; primers included |
[11] | Yang 2020 | Not reported how 13 patients for serial sampling IPD data chosen | 51 | 52 |  | 2–86 | Mixed URT (nasal swabs, throat swabs) and mixed LRT (sputum and bronchoalveolar lavage fluid (BALF)) | qRT-PCR; GeneoDX Co. | Not reported; not reported |
[26] | Young 2020 | IPD of all patients in study | 50 | 47 |  | 31–73 | Nasopharyngeal, faeces, urine, blood | qRT-PCR; not reported | ORF1ab, N-gene, S-gene; primers included |
[22] | Yuan 2020 | IPD of all patients in study | 33 | 64 | 59 | 36–71 | Nasopharyngeal, faeces | qRT-PCR; not reported | E-gene, RdRp, N-gene; not reported |
[25] | Zhang 2020a | Not reported | NR | NR | NR | NR | URT (oral), faeces | qRT-PCR; HiScript®II One Step qRT-PCR SYBR®Green Kit (Vazyme Biotech Co.) | S-gene; primer included |
[35] | Zhang 2020b | IPD of all patients in study | 86 | 26 | 22 | 10 months–35 years | Throat, faeces, blood | qRT-PCR; not reported | Not reported; not reported |
[38] | Zheng 2020 | IPD of all patients in study | 60 | 55 | NR | NR | Sputum, faeces, blood | qRT-PCR; SARS-CoV-2 detection kit (BoJie Shanghai) | ORF1ab; not reported |
[15] | Zou 2020 | IPD of almost all patients in study | 50 | 59 |  | 26–76 | Throat, URT (nasal) | qRT-PCR; not reported | ORF1ab, N-gene; not reported |